{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:47:53Z","timestamp":1793213273991,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T00:00:00Z","timestamp":1511136000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s11920-017-0859-6","type":"journal-article","created":{"date-parts":[[2017,11,19]],"date-time":"2017-11-19T19:53:21Z","timestamp":1511121201000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["ADHD and Anxiety: Clinical Significance and Treatment Implications"],"prefix":"10.1007","volume":"19","author":[{"given":"Frederick W.","family":"Reimherr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barrie K.","family":"Marchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Gift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy A.","family":"Steans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,20]]},"reference":[{"issue":"2","key":"859_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s12402-014-0128-z","volume":"6","author":"C Jacob","year":"2014","unstructured":"Jacob C, et al. Internalizing and externalizing behavior in adult ADHD. Atten Defic Hyperact Disord. 2014;6(2):101\u201310. \nhttps:\/\/doi.org\/10.1007\/s12402-014-0128-z\n\n.","journal-title":"Atten Defic Hyperact Disord."},{"issue":"2","key":"859_CR2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.biopsych.2005.04.040","volume":"58","author":"FW Reimherr","year":"2005","unstructured":"\u2022 Reimherr FW, et al. Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry. 2005;58(2):125\u201331. This is the first study documenting that high levels of emotional dysregulation can exist in adults with ADHD even when anxiety and depression disorders are carefully excluded. Emotional dysregulation improved even though measures of anxiety and depression did not","journal-title":"Biol Psychiatry"},{"issue":"4","key":"859_CR3","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1176\/ajp.2006.163.4.716","volume":"163","author":"RC Kessler","year":"2006","unstructured":"Kessler RC, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716\u201323.","journal-title":"Am J Psychiatry"},{"issue":"12","key":"859_CR4","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1177\/1087054713518240","volume":"20","author":"B Pi\u00f1eiro-Dieguez","year":"2016","unstructured":"\u2022 Pi\u00f1eiro-Dieguez B, et al. Psychiatric comorbidity at the time of diagnosis in adults with ADHD: the CAT study. J Atten Disord. 2016;20(12):1066\u201375. In a large sample of adults ADHD (\n                        n\u00a0=\u00a0367), additional psychiatric diagnoses were present in 66.2% of the sample. The most common were substance use disorders (39.2%) and anxiety disorders (23%)","journal-title":"J Atten Disord"},{"issue":"4","key":"859_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1755-5949.2010.00148.x","volume":"17","author":"M Ameringen Van","year":"2011","unstructured":"\u2022 Van Ameringen M, et al. Adult attention deficit hyperactivity disorder in an anxiety disorders population. CNS Neurosci Ther. 2011;17(4):221\u20136. \nhttps:\/\/doi.org\/10.1111\/j.1755-5949.2010.00148.x\n\n. In an anxiety clinic, a sample of 129 patients were assessed for the presence of adult ADHD; 27.9% had both disorders","journal-title":"CNS Neurosci Ther"},{"key":"859_CR6","first-page":"125","volume-title":"Attention-deficit disorders and comorbidities in children, adolescents, and adults","author":"R Tannock","year":"2000","unstructured":"Tannock R. Attention-deficit\/hyperactivity disorder with anxiety disorders. In: Brown TE, editor. Attention-deficit disorders and comorbidities in children, adolescents, and adults. Washington, DC: American Psychiatric Press; 2000. p. 125\u201370."},{"issue":"1","key":"859_CR7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1207\/S15374424JCCP3301_5","volume":"33","author":"JT Nigg","year":"2004","unstructured":"Nigg JT, Goldsmith HH, Sachek J. Temperament and attention deficit hyperactivity disorder: the development of a multiple pathway model. J Clin Child Adolesc Psychol. 2004;33(1):42\u201353.","journal-title":"J Clin Child Adolesc Psychol"},{"issue":"12","key":"859_CR8","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1176\/ajp.152.12.1793","volume":"152","author":"S Milberger","year":"1995","unstructured":"\u2022 Milberger S, et al. Attention deficit hyperactivity disorder and comorbid disorders: issues of overlapping symptoms. Am J Psychiatry. 1995;152(12):1793\u20139. In large sample of children, adolescents, and adults with ADHD and a comorbid psychiatric disorder, 75% maintained their diagnosis of generalized anxiety disorder when overlapping symptoms were removed","journal-title":"Am J Psychiatry"},{"key":"859_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.eurpsy.2015.08.007","volume":"35","author":"T Cadman","year":"2016","unstructured":"Cadman T, et al. Six-year follow-up study of combined type ADHD from childhood to young adulthood: predictors of functional impairment and comorbid symptoms. Eur Psychiatry. 2016;35:47\u201354. \nhttps:\/\/doi.org\/10.1016\/j.eurpsy.2015.08.007\n\n.","journal-title":"Eur Psychiatry"},{"issue":"2","key":"859_CR10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00004583-200102000-00009","volume":"40","author":"PS Jensen","year":"2001","unstructured":"Jensen PS, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J. Am. Acad. Child Adolesc Psychiatry. 2001;40(2):147\u201358.","journal-title":"J. Am. Acad. Child Adolesc Psychiatry"},{"issue":"6","key":"859_CR11","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1023\/A:1005179014321","volume":"28","author":"JS March","year":"2000","unstructured":"March JS, et al. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). J Abnorm Child Psychol. 2000;28(6):527\u201341.","journal-title":"J Abnorm Child Psychol"},{"issue":"5","key":"859_CR12","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00004583-199505000-00017","volume":"34","author":"LL Barrickman","year":"1995","unstructured":"Barrickman LL, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;34(5):649\u201357.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"859_CR13","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/chi.0b013e3180ca8385","volume":"46","author":"D Geller","year":"2007","unstructured":"Geller D, et al. Atomoxetine treatment for pediatric patients with attention-deficit\/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(9):1119\u201327.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"859_CR14","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/ped.12847","volume":"58","author":"E Snircova","year":"2016","unstructured":"Snircova E, et al. Anxiety reduction on atomoxetine and methylphenidate medication in children with ADHD. Pediatr Int. 2016;58(6):476\u201381. \nhttps:\/\/doi.org\/10.1111\/ped.12847\n\n.","journal-title":"Pediatr Int"},{"issue":"3","key":"859_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s12402-012-0078-2","volume":"4","author":"K Moshe","year":"2012","unstructured":"Moshe K, Karni A, Tirosh E. Anxiety and methylphenidate in attention deficit hyperactivity disorder: a double-blind placebo-drug trial. Atten Defic Hyperact Disord. 2012;4(3):153\u20138. \nhttps:\/\/doi.org\/10.1007\/s12402-012-0078-2\n\n.","journal-title":"Atten Defic Hyperact Disord."},{"issue":"5","key":"859_CR16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/070674371005500506","volume":"55","author":"M Ter-Stepanian","year":"2010","unstructured":"Ter-Stepanian M, et al. Clinical response to methylphenidate in children diagnosed with attention-deficit hyperactivity disorder and comorbid psychiatric disorders. Can J Psychiatr. 2010;55(5):305\u201312.","journal-title":"Can J Psychiatr"},{"issue":"5","key":"859_CR17","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1542\/peds.2013-3686","volume":"133","author":"E Sciberras","year":"2014","unstructured":"Sciberras E, et al. Anxiety in children with attention-deficit\/hyperactivity disorder. Pediatrics. 2014;133(5):801\u20138. \nhttps:\/\/doi.org\/10.1542\/peds.2013-3686\n\n.","journal-title":"Pediatrics"},{"key":"859_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/NDT.S115707","volume":"13","author":"DB Clemow","year":"2017","unstructured":"Clemow DB, et al. A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities. Neuropsychiatr Dis Treat. 2017;13:357\u201371. \nhttps:\/\/doi.org\/10.2147\/NDT.S115707\n\n.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"859_CR19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/1087054712474949","volume":"21","author":"Y Bloch","year":"2017","unstructured":"Bloch Y, et al. Methylphenidate reduces state anxiety during a continuous performance test that distinguishes adult ADHD patients from controls. J Atten Disord. 2017;21(1):46\u201351.","journal-title":"J Atten Disord"},{"issue":"8","key":"859_CR20","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1177\/070674370304800806","volume":"48","author":"R Bouffard","year":"2003","unstructured":"Bouffard R, et al. The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Can J Psychiatr. 2003;48(8):546\u201354.","journal-title":"Can J Psychiatr"},{"issue":"5","key":"859_CR21","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1177\/1087054711434772","volume":"17","author":"P Mattos","year":"2013","unstructured":"Mattos P, et al. A multicenter, open-label trial to evaluate the quality of life in adults with ADHD treated with long-acting methylphenidate (OROS MPH): Concerta Quality of Life (CONQoL) study. J Atten Disord. 2013;17(5):444\u20138. \nhttps:\/\/doi.org\/10.1177\/1087054711434772\n\n.","journal-title":"J Atten Disord"},{"issue":"2","key":"859_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12402-010-0025-z","volume":"2","author":"A Gabriel","year":"2010","unstructured":"\u2022 Gabriel A. The mixed amphetamine salt extended release (Adderall XR, Max-XR) as an adjunctive to SSRIS or SNRIS in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety: an open-label study. Atten Defic Hyperact Disord. 2010;2(2):87\u201392. \nhttps:\/\/doi.org\/10.1007\/s12402-010-0025-z\n\n. A sample of adults with ADHD and generalized anxiety who showed a partial response to a SSRI or a SNRI were then treated with extended mixed amphetamine salts. The HAMA, ADHD rating scale, and CGI all showed additional improvement","journal-title":"Atten Defic Hyperact Disord"},{"issue":"4","key":"859_CR23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s12402-011-0063-1","volume":"3","author":"A Gabriel","year":"2011","unstructured":"Gabriel A, Violato C. Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study. Atten Defic Hyperact Disord. 2011;3(4):319\u201326. \nhttps:\/\/doi.org\/10.1007\/s12402-011-0063-1\n\n.","journal-title":"Atten Defic Hyperact Disord"},{"issue":"6","key":"859_CR24","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4088\/JCP.v61n0604","volume":"61","author":"JP Horrigan","year":"2000","unstructured":"Horrigan JP, Barnhill LJ. Low-dose amphetamine salts and adult attention-deficit\/hyperactivity disorder. J Clin Psychiatry. 2000;61(6):414\u20137.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"859_CR25","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3109\/15622971003624197","volume":"11","author":"M R\u00f6sler","year":"2010","unstructured":"\u2022 R\u00f6sler M, et al. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD. World J Biol Psychiatry. 2010;11(5):709\u201318. \nhttps:\/\/doi.org\/10.3109\/15622971003624197\n\n. In this large multi-center study, while there was a significant reduction in ADHD symptoms, there was no difference in change in anxiety symptoms between placebo and methylphenidate","journal-title":"World J Biol Psychiatry"},{"issue":"1","key":"859_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/JCP.0b013e31827d8a23","volume":"33","author":"TM Durell","year":"2013","unstructured":"Durell TM, et al. Atomoxetine treatment of attention-deficit\/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol. 2013;33(1):45\u201354. \nhttps:\/\/doi.org\/10.1097\/JCP.0b013e31827d8a23\n\n.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"859_CR27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/1087054712443157","volume":"18","author":"M Bilodeau","year":"2014","unstructured":"Bilodeau M, et al. Duloxetine in adults with ADHD: a randomized, placebo-controlled pilot study. J Atten Disord. 2014;18(2):169\u201375. \nhttps:\/\/doi.org\/10.1177\/1087054712443157\n\n.","journal-title":"J Atten Disord"},{"issue":"2","key":"859_CR28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12402-015-0176-z","volume":"7","author":"FW Reimherr","year":"2015","unstructured":"\u2022 Reimherr FW, et al. Types of adult attention-deficit hyperactivity disorder (ADHD): baseline characteristics, initial response, and long-term response to treatment with methylphenidate. Atten Defic Hyperact Disord. 2015;7(2):115\u201328. \nhttps:\/\/doi.org\/10.1007\/s12402-015-0176-z\n\n. We proposed that adult ADHD should be divided into ADHD Inattentive Presentation and Emotional Dysregulation Presentation","journal-title":"Atten Defic Hyperact Disord"},{"key":"859_CR29","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1176\/ajp.94.3.577","volume":"94","author":"C Bradley","year":"1937","unstructured":"Bradley C. The Behavior of Children Receiving Benzedrine. Am J Psychiatry. 1937;94:577\u201381.","journal-title":"Am J Psychiatry."},{"key":"859_CR30","unstructured":"Wender PH. Minimal Brain Dysfunction in Children: Wiley-Interscience; 1971."},{"issue":"2","key":"859_CR31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.biopsych.2005.04.040","volume":"58","author":"FW Reimherr","year":"2005","unstructured":"Reimherr FW, et al. Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry. 2005;58(2):125\u201331.","journal-title":"Biol Psychiatry"},{"key":"859_CR32","volume-title":"Attention-deficit hyperactivity disorder in adults. New York","author":"PH Wender","year":"1995","unstructured":"Wender PH. Attention-deficit hyperactivity disorder in adults. New York. NY: Oxford University Press; 1995."},{"issue":"4","key":"859_CR33","first-page":"267","volume":"27","author":"BK Marchant","year":"2015","unstructured":"Marchant BK, et al. Psychometric properties of the self-report Wender-Reimherr Adult Attention Deficit Disorder Scale. Ann Clin Psychiatry. 2015;27(4):267\u201377. 26554368","journal-title":"Ann Clin Psychiatry"},{"issue":"3","key":"859_CR34","first-page":"245","volume":"1","author":"FW Reimherr","year":"2005","unstructured":"Reimherr FW, et al. Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial. Neuropsychiatr Dis Treat. 2005;1(3):245\u201351.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1\u20132","key":"859_CR35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.drugalcdep.2008.02.009","volume":"96","author":"TE Wilens","year":"2008","unstructured":"Wilens TE, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend. 2008;96(1\u20132):145\u201354. \nhttps:\/\/doi.org\/10.1016\/j.drugalcdep.2008.02.009\n\n.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"859_CR36","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s00406-008-0845-4","volume":"259","author":"M Rosler","year":"2008","unstructured":"Rosler M, et al. A randomized, placebo-controlled,24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit\/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci. 2008;259(2):120\u20139. \nhttps:\/\/doi.org\/10.1007\/s00406-008-0845-4\n\n.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"1","key":"859_CR37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/1087054709356188","volume":"15","author":"PH Wender","year":"2011","unstructured":"Wender PH, et al. One year trial of methylphenidate in adult ADHD. J Atten Disord. 2011;15(1):36\u201345.","journal-title":"J Atten Disord"},{"issue":"3","key":"859_CR38","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1037\/a0032797","volume":"25","author":"BK Marchant","year":"2013","unstructured":"Marchant BK, et al. Psychometric properties of the Wender-Reimherr Adult Attention Deficit Disorder Scale. Psychol Assess. 2013;25(3):942\u201350.","journal-title":"Psychol Assess"},{"key":"859_CR39","volume-title":"Conners\u2019 Adult ADHD Rating Scales (CAARS)","author":"CK Conners","year":"1999","unstructured":"Conners CK, Erhardt D, Sparrow EP. Conners\u2019 Adult ADHD Rating Scales (CAARS). Multi-Health Systems: North Tonawanda, NY; 1999."},{"issue":"1","key":"859_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/1087054709347435","volume":"14","author":"TJ Spencer","year":"2010","unstructured":"Spencer TJ, et al. Validation of the adult ADHD investigator symptom rating scale (AISRS). J Atten Disord. 2010;14(1):57\u201368. \nhttps:\/\/doi.org\/10.1177\/1087054709347435\n\n.","journal-title":"J Atten Disord"},{"key":"859_CR41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"MA Hamilton","year":"1959","unstructured":"Hamilton MA. The assessment of anxiety states by rating. Br J Med Psychology. 1959;32:50\u20135. \nhttps:\/\/doi.org\/10.1111\/j.2044-8341.1959.tb00467.x\n\n.","journal-title":"Br J Med Psychology"},{"key":"859_CR42","first-page":"679","volume-title":"The use of psychological testing for treatment planning and outcomes assessment","author":"LR Derogatis","year":"1999","unstructured":"Derogatis LR, Savitz KL. The SCL-90-R, brief symptom inventory and matching clinical rating scales. In: Maruish ME, editor. The use of psychological testing for treatment planning and outcomes assessment. Philadelphia: Lawrence Erlbaum; 1999. p. 679\u2013724."},{"issue":"6","key":"859_CR43","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1097\/JCP.0b013e3181c00b1e","volume":"29","author":"MM Victor","year":"2009","unstructured":"Victor MM, et al. Reasons for pretreatment attrition and dropout from methylphenidate in adults with attention-deficit\/hyperactivity disorder: the role of comorbidities. J Clin Psychopharmacol. 2009;29(6):614\u20136. \nhttps:\/\/doi.org\/10.1097\/JCP.0b013e3181c00b1e\n\n.","journal-title":"J Clin Psychopharmacol"},{"key":"859_CR44","doi-asserted-by":"crossref","unstructured":"Gift T, et al. Personality disorder in adult attention-deficit\/hyperactivity disorder: attrition and change during long-term treatment. J Nerv Ment Dis. 2016;204(5):355\u2013363.","DOI":"10.1097\/NMD.0000000000000470"},{"issue":"2","key":"859_CR45","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/JCP.0000000000000091","volume":"34","author":"MM Victor","year":"2014","unstructured":"Victor MM, et al. Attrition and dropout from methylphenidate in adults with attention-deficit\/hyperactivity disorder the role of comorbidities. J Clin Psychopharmacol. 2014;34(2):212\u20137.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"859_CR46","first-page":"94","volume":"22","author":"RJ Robison","year":"2010","unstructured":"Robison RJ, et al. Personality disorders in ADHD part 2: the effect of symptoms of personality disorder on response to treatment with OROS methylphenidate in adults with ADHD. Ann Clin Psychiatry. 2010;22(2):94\u2013102.","journal-title":"Ann Clin Psychiatry"},{"key":"859_CR47","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.psychres.2016.05.009","volume":"214","author":"A Segev","year":"2016","unstructured":"Segev A, et al. A possible effect of methylphenidate on state anxiety: a single dose, placebo controlled, crossover study in a control group. Psychiatry Res. 2016;214:232\u20135.","journal-title":"Psychiatry Res"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11920-017-0859-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-017-0859-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-017-0859-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T21:42:26Z","timestamp":1512423746000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11920-017-0859-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,20]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["859"],"URL":"https:\/\/doi.org\/10.1007\/s11920-017-0859-6","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,20]]},"article-number":"109"}}